By Chris Wack

Innate Pharma shares were up 8% to $3.25 after Sanofi said that the U.S. Food and Drug Administration has granted Fast Track Designation for SAR'579/IPH6101 for the treatment of hematological malignancies.

Fast Track Designation is an FDA process designed to facilitate the development, and expedite the review of, medicines to treat serious conditions and fill unmet medical need.

SAR'579 is a trifunctional anti-CD123 cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 08, 2023 10:38 ET (14:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Innate Pharma (EU:IPH)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Innate Pharma.
Innate Pharma (EU:IPH)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Innate Pharma.